

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The effects of flexi-bar training on muscle strength and physical performance in the older people with dynapenia: protocol of a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-048629
Article Type:	Protocol
Date Submitted by the Author:	02-Jan-2021
Complete List of Authors:	WEI, Ning; Wuhan Polytechnic University, CHEN, Ling; Wuhan Polytechnic University Wang, Xinxin; Wuhan Polytechnic University Lyu, Mengyu; Wuhan Polytechnic University
Keywords:	REHABILITATION MEDICINE, GERIATRIC MEDICINE, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 Protocol

5
6 The effects of flexi-bar training on muscle strength and physical performance in
7
8
9 the older people with dynapenia: protocol of a randomized controlled trial

10
11 Ning Wei*. Room 309, Department of Rehabilitation Sciences, College of Health
12
13 Science & Nursing, Wuhan Polytechnic University, Hubei, China. Email:
14
15 Nicole.weining@whpu.edu.cn; Tel: +86-83956736; Fax: +86-83956736.
16
17

18
19 Xinxin Wang. Department of Rehabilitation Sciences, College of Health Science & Nursing,
20
21 Wuhan Polytechnic University, Hubei, China.
22
23

24
25 Ling Chen. Department of Rehabilitation Sciences, College of Health Science & Nursing,
26
27 Wuhan Polytechnic University, Hubei, China.
28
29

30
31 Mengyu Lyu. Department of Rehabilitation Sciences, College of Health Science & Nursing,
32
33 Wuhan Polytechnic University, Hubei, China.
34

35 **Correspondence should be sent to Ning Wei.**
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Dynapenia is a relative new term, which is used to describe age-related loss of muscle strength. Flexi-bar training is a safe and feasible device for the older people with dynapenia. The objective of this study is to investigate the effects of 4-week flexi-bar training program on muscle strength and physical function in the older people with dynapenia.

Methods and analysis: One hundred and fourteen participants (aged above 65 years old) with age-related muscle loss will be randomly divided into 3 equal groups, namely, flexi-bar group, placebo group and control group to participate a 4-week flexi-bar training program. Assessments will be done at pre-, post-intervention and 4 weeks after training completion including Timed-up-and-go test, five-repetition sit-to-stand and 10-meter walking test. The levels of serum albumin and hemoglobin will be measured at pre- and post-intervention.

Ethics and dissemination: The procedures of this study were reviewed and approved by the Human Ethics Review Board of Wuhan Brain Hospital (General Hospital of the Yangtze River Shipping) on 29th Sep 2020 (L20200013). The findings of this study will be published in peer-reviewed journals and presented at conferences.

Word count: 2144

Trial registration number is ISRCTN 14316668. It was registered on 6th Nov 2020.
<https://doi.org/10.1186/ISRCTN14316668>

Strengths and limitations of this study

- This is the first study to investigate the effects of flexi-bar training on

1
2
3
4 muscle strength and physical performance in the older population with dynapenia.
5

6 ● In this study, we will try to find whether 4-week flexi-bar training would
7
8 influence the level of albumin and hemoglobin, which might explain the effect of
9
10 flexi-bar training on the muscle strength in the older people with dynapenia.
11
12

13
14 ● The muscle loading might be insufficient for some participants since the
15
16 flexi-bar is an active induced training device.
17
18

19 Key words: rehabilitation medicine, geriatric medicine, musculoskeletal disorders
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Dynapenia is defined as age-related loss of muscle strength, which was proposed by Clark and Manini in 2008.[1] The prevalence of dynapenia was more than 20% in some countries.[2,3] Age-related loss of muscle strength was strongly associated with high risk of falls [4], poor physical performance,[5,6] disability [7] and mortality.[8] The incidence of falls among dynapenic older people was 17.2%.[4] Hasselgren et al. (2011) reported the score of Berg Balance Scale and Physiotherapy Clinical Outcome Variable Scale were significantly correlated with muscle strength in the very old people.[5] Newman et al. (2006) found muscle strength, not muscle mass, was strongly related to mortality in the older people.[8] Some recent studies have found that long-term exercise training program could improve both muscle and functional performance in older people with dynapenia.[9-12]

Flexi-bar is one type of vibration training. It consists of a bar and two weighty rubbers at each end of the bar. Its frequency is 5 Hz.[13] Compared to conventional training, it is portable and feasible for physical training in the older population, especially those with dynapenia. Some previous studies have found long-term flexi-bar had positive effects on muscle mass in young people [14] and physical function in old people.[15,16] It was reported that the thickness of transversus abdominis muscle of young university adults increase 2.4 mm after 6-month (48 times) flexi-bar training program, which was statistically significantly different from the control group (0.9mm).[14] Lee et al. (2018) found the score of BBS increased 3.2, the duration of completion TUG and 10MWT significantly decreased 4.2s and 4.6s, respectively, after 4 weeks flexi-bar training (20 times), in older people with chronic stroke.[15] For muscle strength, although there was no direct evidence, Meliva et al. (2010) recorded the EMG of biceps brachii, triceps brachii, rectus femoris, and vastus lateralis during

1
2
3 one set of flexi-bar training and concluded that Flexi-bar training could induce a
4 stronger training stimulus on the muscle during submaximal exercise.[13] This findings
5 can give a hint that flexi-bar training might be effective approach to enhance muscle
6 strength with submaximal level.
7
8
9
10

11
12 Regarding to the findings of the previous studies, flexi-bar might be an effective
13 and safe training device for the older people with dynapenia. Considering the limited
14 studied conducted in the population with dynapenia, it is meaningful to examine the
15 effects of flexi-bar on muscle and physical performance in the older people with
16 dynapenia. The objective of this study is to investigate the effects of 4-week flexi-bar
17 training program on muscle strength and physical function in the older people with
18 dynapenia.
19
20
21
22
23
24
25
26
27

28 **METHOSD AND ANALYSIS**

29 **Participants**

30
31
32
33 The advertisement will be put on the notice board in the Health Service Centers in
34 General Hospital of the Yangtze River Shipping, Wuhan. Participants aged 65 years or
35 above attending the Health Center will be invited to a screening test of handgrip
36 strength measurement. Men and women with muscle strength less than 26kg and 18kg,
37 respectively, will be diagnosed as dynapenia.[17] Participants with severe heart
38 problem, neuro-degenerative diseases, vestibular disorders, cognitive impairment,
39 severe osteoporosis, visual impairment or mental diseases will be excluded from this
40 study. All participants will give their written consent to the principal investigator (NW)
41 before participating in the study. Only the principal investigator (NW) can access the
42 personal information of the study participants, which will be kept confidentially during
43 and after the study. The procedures were reviewed and approved by the Human Ethics
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Review Board of Wuhan Brain Hospital (General Hospital of the Yangtze River
5
6 Shipping) prior to commencement of the study (#L20200013). The clinical registration
7
8 number is ISRCTN 14316668 on 6th Nov 2020.
9
10 <https://doi.org/10.1186/ISRCTN14316668>
11
12

13 14 Randomization and blinding

15
16 This protocol was designed as a single-blinded randomized controlled trial and
17
18 adheres to SPIRIT guidelines. The participants will be randomized to flexi-bar group,
19
20 sham group and control group (no training). Each participants will be given an
21
22 identification number by the main investigator (NW), who performed the
23
24 randomization with a computer program (Research Randomizer Form
25
26 www.randomizer.org/). All training sessions will be conducted under the supervision
27
28 of a physical therapist, who will be blinded to the randomization. The assessments and
29
30 data analysis will be performed by a researcher (XXW). Two research assistant (LC
31
32 and MYLyu) will be responsible for data entry (double data entry). Both of them will
33
34 be blinded to randomization and intervention.
35
36
37
38
39
40
41
42

43 Patient and public involvement

44
45 Patients or members of the public will not be involved in this study. The research
46
47 design, enrolment, allocation, interventions and assessments will be conducted by the
48
49 trained researchers and physical therapists.
50
51

52 Interventions

53
54 A total of 20 training sessions (5 days/week, 4 weeks) will be conducted in Health
55
56 Service Centers. Each training session will include 10 sets of 30-second vibration or
57
58
59
60

1
2
3
4 sham exercise. One minute of rest period will be given between training set to avoid
5
6 over exertion of the participants. During training, the flexi-bar group will hold a Flexi-
7
8 Bar (FLEXI-BAR®; Flexi-Sports, Germany) with shoulder flexed 90° to perform an
9
10 up-and-down vibration exercise. The sham group will hold the same flexi-bar with no
11
12 active vibration workout. During the training sessions, the participants will be asked to
13
14 stand with knee angle of 120°. In order to cater for mission appointments, extra sessions
15
16 will be arranged to make sure all participants will complete the same number of
17
18 training sessions. The training sessions will be supervised by a physical therapist, who
19
20 will be blinded to the randomization. Any adverse event will be reported to the Human
21
22 Ethics Review Board of Wuhan Brain Hospital (General Hospital of the Yangtze River
23
24 Shipping). The control group will receive no additional exercise training during the
25
26 study. All participants will be asked to keep their lifestyle as usual.
27
28
29
30
31
32
33
34

35 Outcome variables

36
37 The assessments, including handgrip muscle strength, five-repetition sit-to-stand
38
39 test (5STS), 10-meter walking test (10MWT) and timed-up-and-go test (TUG) will be
40
41 conducted at baseline, post-intervention (one day after training completion) and 4
42
43 weeks after training completion to investigate the effects of flexi-bar training on
44
45 physical performance in the older people with dynapenia. The levels of serum albumin
46
47 and hemoglobin will be examined at baseline and post-intervention (one day after
48
49 training completion) to explore the possible mechanisms of flexi-bar training on muscle
50
51 strength. The study plan for recruitment, interventions, assessment for the participants
52
53 are summarized in Table 1.
54
55
56
57
58
59
60

Table 1 Timetable of activities planned during the study.

TIMEPOINT	STUDY PERIOD					
	Enrolment	Allocation	Post-allocation			Close-out
	Day 0	week 0	Week 4	Week 8	After Week 8	
ENROLMENT:						
Eligibility screen	X					
Informed consent	X					
Randomization	X					
Allocation	X					
INTERVENTIONS:						
Flexi-bar group		←————→				
Sham group		←————→				
Control group		←————→				
ASSESSMENTS:						
Five-repetition sit-to-stand test		X	X	X		
10-meter walking test		X	X	X		
Timed-up-and-go test		X	X	X		
serum albumin		X	X	X		
hemoglobin		X	X			

Maximum muscle strength of dominant side was measured by hand-held dynamometry (kg; CAMRY® Model EH101). Participants were asked to stand straight with arms close to the body and the elbow flexed at 90°. Participants were instructed to squeeze the dynamometer as hard as possible. The maximum value of three trails will

1
2
3
4 be used for analyses.
5

6 The timed-up and go test (TUG) was recommended as a suitable assessment for
7 balance and physical function in the older people with low muscle strength.[18]
8
9 Participants performed this test with their regular footwear. They stand up from an
10
11 armchair, walk a distance of 3 meters, turn and walk back to the chair, and sit down
12
13 with their normal pace without help from another person. The average time of two trials
14
15 will be used in the data analysis.
16
17
18
19
20
21

22 The five-repetition sit-to-stand test (5STS) is a reliable and valid assessment for
23 physical function.[18] The participant sat on a chair of 43-47cm high with back against
24
25 the chair, arms crossed on the chest, feet comfortably placed on the floor. When the
26
27 tester said“start”, the participant would rise from the chair to assume a full standing
28
29 position and return to a sitting position for five times without rest in between. The time
30
31 taken to complete the test will be recorded and the average time of two tests will be
32
33 calculated.
34
35
36
37
38
39

40 10-meter walking test will be assessed at self-preferred and maximum walking
41
42 speed. It is used as a golden tool to evaluate the mobility in the older people.[18] The
43
44 time was measured only for the middle 6 meters. Walking aid was allowed in this test.
45
46
47 The average walking speed of three trials was used in the data analysis.
48
49

50 The levels of serum albumin and hemoglobin will be measured in complete blood
51
52 count. Blood will be collected from the antecubital vein with participants seated after a
53
54 12-hour fasting period. After collection, tubes containing ethylenediamine tetra-
55
56 aceticacid plus samples will be centrifuged at 3.000 g for 15 min and plasma aliquots
57
58
59
60

1
2
3
4 stored at -70°C until analysis.
5

6 Sample size calculation 7

8
9 Until now, there was no study examined the long-term effects of Flexi-bar training
10 in the older people with dynapenia. Thus, this study adopted an effect size of 0.27 to
11 estimate the sample size, which was reported in a previous study investigating the
12 effects of 12-week power training program on TUG in the older people with dynapenia
13 [10]. Since this study involved two groups and three times of assessments, the sample
14 size for each group was calculated as 30 with a power of 0.8 and α value of 0.05. In
15 consideration of 20% dropout rate, the total sample size was 114.
16
17
18
19
20
21
22
23
24
25

26 Patient and public involvement 27

28 Patients or members of the public will not be involved in this study. The research
29 design, enrolment, allocation, interventions and assessments will be conducted by the
30 trained researchers.
31
32
33
34
35

36 Data analysis 37

38 To compare the baseline characteristics of the three groups, one-way ANOVA (for
39 data with normal distribution) or Kruskal-Wallis test (for data with non-normal
40 distribution) will be conducted. Two-way repeated measures ANOVA (time \times group)
41 or Friedman test will be used to explore the effect of Flexi-bar training on muscle
42 strength and physical performance in the people with dynapenia. The last observation
43 carried forward of an intention-to-treat analysis will be used for data analysis.
44
45
46
47
48
49
50
51
52
53
54
55
56 Descriptive analyses will be reported as means \pm standard deviations. SPSS 20.0 (SPSS
57 Inc., Chicago, Illinois, USA) will be used for statistical analysis. Significance level will
58
59
60

1
2
3
4 be set at $p < 0.05$, unless otherwise state.

5 6 **DISCUSSION**

7
8 To our knowledge, it is the first study to investigate the effects of flexi-bar training
9
10 on muscle strength and physical performance in the older people with dynapenia. Two
11
12 previous studies had investigated the effects of flexi-bar training physical performance
13
14 in the old people.[15,16] They had reported that the performance in TUG and 10MWT
15
16 were improved after long-term flexi-bar training.[15] However, there was no placebo
17
18 group in their studies. Thus, it is premature to draw a conclusion from this two studies.
19
20

21
22 Some previous studies had pointed that the older people with lower muscles strength
23
24 would have lower levels of albumin and hemoglobin.[19-21] One population-based
25
26 cross-sectional study reported serum albumin and hemoglobin was positively
27
28 associated with muscle strength and balance, but negatively with IADL in the
29
30 community dwelling aged 55 and above.[19]
31
32

33
34 The strengths of this study are as below: first, this is the first study to investigate the
35
36 effects of flexi-bar training on muscle strength and physical performance in the older
37
38 population with dynapenia. In this study, we will try to find whether 4-week flexi-bar
39
40 training would influence the level of albumin and hemoglobin, which might explain
41
42 the effect of flexi-bar training on the muscle strength in the older people with
43
44 dynapenia. Second, there will be a placebo group in this study, which can rule out the
45
46 effect of static squatting. The limitations of this study are as below: First, the muscle
47
48 loading might be insufficient for some participants since the flexi-bar is an active
49
50 induced training device. However, the participant in this study will be the older
51
52 people with dynapenia at different phase. Thus, unified muscle loading might not
53
54
55
56
57
58
59
60

1
2
3
4 suitable for our participants. Second, the training will conduct 5 times per week for 4
5
6 weeks, which might be too intensive to induce high drop-out rate.
7

8 **ACKNOWLEDGEMENT**

9
10 We would thank doctors, nurses and physical therapists of Department of
11
12 Rehabilitation of Wuhan Brain Hospital (General Hospital of the Yangtze River
13
14 Shipping) for their assistance.
15

16 **CONTRIBUTORS**

17
18 NW made substantial contributions to conception and design. XXW, MYL and
19
20 LC will collect and analyze data. The manuscript was drafted by NW.
21
22

23 **FUNDING STATEMENT**

24
25 This work was supported by Natural Science Foundation of Hubei Province
26
27 (Project #2019CFB349).
28
29

30 **ERHICS APPROVAL**

31
32 The Human Ethics Review Board of Wuhan Brain Hospital (General Hospital of
33
34 the Yangtze River Shipping) (#L20200013).
35
36

37 **CONFLICTS OF INTEREST**

38
39 The authors declared no potential conflicts of interest with respect to the research,
40
41 authorship, and/or publication of this article.
42
43

44 **DISSEMINATIONS**

45
46 The findings of this study will be published in peer-viewed journals and presented
47
48 in conferences. Meanwhile, the results will be disseminated to the study participants.
49
50

51 **REFERENCES**

52
53
54 1. Clark BC, Manini TM. Sarcopenia \neq dynapenia. J Gerontol A Biol Sci Med Sci.
55
56 2008;63(8):829-834.
57
58
59
60

- 1
2
3
4 2. Borges VS, Lima-Costa MFF, Andrade FB. A nationwide study on prevalence and
5
6 factors associated with dynapenia in older adults: ELSI-Brazil. *Cad Saude Publica*.
7
8 2020;36(4):e00107319.
9
10
- 11 3. Tessier AJ, Wing SS, Rahme E, et al. Physical function-derived cut-points for the
12
13 diagnosis of sarcopenia and dynapenia from the Canadian longitudinal study on aging.
14
15 *J Cachexia Sarcopenia Muscle*. 2019;10(5):985-999.
16
17
- 18 4. Gadelha AB, Neri SGR, Vainshelboim B, et al. Dynapenic abdominal obesity and
19
20 the incidence of falls in older women: a prospective study. *Aging Clin Exp Res*.
21
22 2020;32(7):1263-1270.
23
24
- 25 5. Hasselgren L, Olsson LL, Nyberg L. Is leg muscle strength correlated with
26
27 functional balance and mobility among inpatients in geriatric rehabilitation? *Arch*
28
29 *Gerontol Geriatr*. 2011;52(3):e220-225.
30
31
- 32 6. Manini TM, Visser M, Won-Park S, et al. Knee extension strength cutpoints for
33
34 maintaining mobility. *J Am Geriatr Soc*. 2007;55(3):451-457.
35
36
- 37 7. Xue QL, Walston JD, Fried LP, et al. Prediction of risk of falling, physical
38
39 disability, and frailty by rate of decline in grip strength: the women's health and aging
40
41 study. *Arch Intern Med*. 2011;171(12):1119-1121.
42
43
- 44 8. Newman AB, Kupelian V, Visser M, et al. Strength, but not muscle mass, is
45
46 associated with mortality in the health, aging and body composition study cohort. *J*
47
48 *Gerontol A Biol Sci Med Sci*. 2006;61(1):72-77.
49
50
- 51 9. Barbat-Artigas S, Filion ME, Dupontgand S, et al. Effects of tai chi training in
52
53 dynapenic and nondynapenic postmenopausal women.
54
55
56
57
58
59
60

1
2
3
4 Menopause. 2011;18(9):974-979.
5

6
7 10. Carvalho LP, Pion CH, El Hajj Boutros G, et al. Effect of a 12-week mixed power
8
9 training on physical function in dynapenic-obese older men: does severity of
10
11 dynapenia matter? Aging Clin Exp Res. 2019;31(7):977-984.
12

13
14 11. Correa CS, Cunha G, Marques N, et al. Effects of strength training, detraining and
15
16 retraining in muscle strength, hypertrophy and functional tasks in older female adults.
17
18 Clin Physiol Funct Imaging. 2016;36(4):306-310.
19

20
21 12. Yamada M, Kimura Y, Ishiyama D, et al. Synergistic effect of bodyweight
22
23 resistance exercise and protein supplementation on skeletal muscle in sarcopenic or
24
25 dynapenic older adults. Geriatr Gerontol Int. 2019;19(5):429-437.
26
27

28
29 13. Mileva KN, Kadr M, Amin N, et al. Acute effects of flexi-bar vs. sham-bar
30
31 exercise on muscle electromyography activity and performance. J Strength Cond Res.
32
33 2010;24(3):737-748.
34
35

36
37 14. Lee SJ, Kim YN, Lee DK. The effect of flexi-bar exercise with vibration on trunk
38
39 muscle thickness and balance in university students in their twenties. J Phys Ther Sci.
40
41 2016;28(4):1298-1302.
42
43

44
45 15. Lee DK, Han JW. Effects of active vibration exercise using a flexi-bar on balance
46
47 and gait in patients with chronic stroke. J Phys Ther Sci. 2018;30(6):832-834.
48
49

50
51 16. Lee DK, Kim YN, Park CB, et al. The effect of actively induced vibration using
52
53 shoulder joint on pain and dysfunction in patients with low back pain. J Phys Ther
54
55 Sci. 2018;30(1):23-26.
56
57

58
59 17. Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian
60

1
2
3
4 Working Group for Sarcopenia. *J Am Med Dir Assoc*. 2014;15(2):95-101.
5

6
7 18. Wei N, Pang MY, Ng SS, et al. Optimal frequency/time combination of whole
8
9 body vibration training for developing physical performance of people
10
11 with sarcopenia: a randomized controlled trial. *Clin Rehabil*. 2017;31(10):1313-1321.
12

13
14 19. Aung KCY, Feng L, Yap KB, et al. Serum albumin and hemoglobin are
15
16 associated with physical function in community-living older persons in Singapore. *J*
17
18 *Nutr Health Aging*. 2011;15(10):877-882.
19

20
21 20. Lee HN, Chang YS, Wu YH, et al. Sarcopenia in female patients with Alzheimer's
22
23 disease are more likely to have lower levels of haemoglobin and 25-hydroxyvitamin
24
25 D. *Psychogeriatrics*. 2020;20(6):858-864.
26
27

28
29 21. Can B, Kara O, Kizilarlanoglu MC, et al. Serum markers of inflammation and
30
31 oxidative stress in sarcopenia. *Aging Clin Exp Res*. 2017;29(4):745-752.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	_____1_____
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	_____2_____
	2b	All items from the World Health Organization Trial Registration Data Set	_____/_____
Protocol version	3	Date and version identifier	_____2_____
Funding	4	Sources and types of financial, material, and other support	_____11_____
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	_____1_____
	5b	Name and contact information for the trial sponsor	_____1_____
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	_____11_____
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	_____/_____

1 **Introduction**

2

3 Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention 3-4

4

5

6 6b Explanation for choice of comparators /

7

8 Objectives 7 Specific objectives or hypotheses 4

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 6

11

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained 5

17

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) 5-6

20

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered 5-6

23

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) /

26

27 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) 6

28

29 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 7

30

31

32 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended 7-8

33

34

35

36

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) 8

41

42

43

44

45

46

1 Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including _____ 10 _____
 2 clinical and statistical assumptions supporting any sample size calculations

3
 4 Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size _____ 5 _____
 5

6 **Methods: Assignment of interventions (for controlled trials)**

7
 8 Allocation:

9
 10 Sequence 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any _____ 6 _____
 11 generation factors for stratification. To reduce predictability of a random sequence, details of any planned restriction
 12 (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants
 13 or assign interventions
 14

15
 16 Allocation 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, _____ 6 _____
 17 concealment opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned
 18 mechanism
 19

20 Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to _____ 6 _____
 21 interventions
 22

23
 24 Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome _____ 5 _____
 25 assessors, data analysts), and how
 26

27 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's _____ 5 _____
 28 allocated intervention during the trial
 29

30
 31 **Methods: Data collection, management, and analysis**

32
 33 Data collection 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related _____ 7-10 _____
 34 methods processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of
 35 study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.
 36 Reference to where data collection forms can be found, if not in the protocol
 37

38
 39 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be _____ / _____
 40 collected for participants who discontinue or deviate from intervention protocols
 41

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	_____6_____
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	_____10_____
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	_____/_____
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	_____10_____
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	_____/_____
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	_____/_____
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	_____7_____
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	_____/_____
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	_____6_____
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	_____/_____
38				
39				
40				
41				
42				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	_____6_____
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	_____/_____
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	_____6_____
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____12_____
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	_____12_____
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	_____/_____
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	_____12_____
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	_____/_____
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____/_____
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	_____/_____
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	_____/_____
35				
36				

37 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.
 40
 41
 42

BMJ Open

The effects of flexi-bar training on muscle strength and physical performance in the older people with dynapenia: protocol of a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-048629.R1
Article Type:	Protocol
Date Submitted by the Author:	20-Apr-2021
Complete List of Authors:	WEI, Ning; Wuhan Polytechnic University, Wang, Xinxin; Wuhan Polytechnic University CHEN, Ling; Wuhan Polytechnic University Lyu, Mengyu; Wuhan Polytechnic University
Primary Subject Heading:	Geriatric medicine
Secondary Subject Heading:	Geriatric medicine
Keywords:	REHABILITATION MEDICINE, GERIATRIC MEDICINE, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 Protocol

5
6 The effects of flexi-bar training on muscle strength and physical performance in
7
8
9 the older people with dynapenia: protocol of a randomized controlled trial

10
11 Ning Wei*. Room 309, Department of Rehabilitation Sciences, College of Health
12
13 Science & Nursing, Wuhan Polytechnic University, Hubei, China. Email:
14
15 Nicole.weining@whpu.edu.cn; Tel: +86-83956736; Fax: +86-83956736.
16
17

18
19 Xinxin Wang. Department of Rehabilitation Sciences, College of Health Science & Nursing,
20
21 Wuhan Polytechnic University, Hubei, China.
22
23

24
25 Ling Chen. Department of Rehabilitation Sciences, College of Health Science & Nursing,
26
27 Wuhan Polytechnic University, Hubei, China.
28
29

30
31 Mengyu Lyu. Department of Rehabilitation Sciences, College of Health Science & Nursing,
32
33 Wuhan Polytechnic University, Hubei, China.
34

35 **Correspondence should be sent to Ning Wei.**
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Dynapenia is a relative new term, which is used to describe the age-related loss of muscle strength. Flexi-bar training is a safe and feasible device for the older people with dynapenia. This study aims to investigate the effects of a 12-week flexi-bar training program on muscle strength and physical function in the older people with dynapenia.

Methods and analysis: One hundred and fourteen participants (aged above 65 years) with age-related muscle loss will be randomly divided into three equal groups, namely, flexi-bar, placebo and control to participate in a 12-week flexi-bar training program. The primary outcomes will be measured at pre-, post-intervention and 12 weeks after training completion including Timed-up-and-go test, five-repetition sit-to-stand and 10-meter walking test. The levels of serum albumin and hemoglobin will be measured as the secondary outcomes at pre- and post-intervention.

Ethics and dissemination: The procedures of this study were reviewed and approved by the Human Ethics Review Board of Wuhan Brain Hospital (General Hospital of the Yangtze River Shipping) on 29th Sep 2020 (L20200013). The findings of this study will be published in peer-reviewed journals and presented at conferences.

Word count: 2268

Trial registration number is ISRCTN 14316668. It was registered on 6th Nov 2020.

<https://doi.org/10.1186/ISRCTN14316668>

Strengths and limitations of this study

- This study is the first parallel randomized controlled trial for this topic,

1
2
3
4 and a placebo group is added in this study design.
5

6 ● This study, including 12-week flexi-bar training and 12-week follow-up,
7
8
9 is sufficient to examine the effects of flexi-bar on older people with dynapenia.
10

11 ● The first limitation of this study might be the unified muscle loading.
12

13
14 ● The second limitation would be the single-blinded design.
15
16

17 Key words: rehabilitation medicine, geriatric medicine, musculoskeletal disorders
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

INTRODUCTION

Dynapenia is defined as age-related loss of muscle strength, which was proposed by Clark and Manini in 2008.[1] The prevalence of dynapenia was more than 20% in some countries.[2,3] The mechanisms of dynapenia are unclear to date. The likely contributors to dynapenia could be age-related neuromuscular impairments.[4] Age-related loss of muscle strength was strongly associated with high risk of falls, [5] poor physical performance,[6,7] disability [8] and mortality.[9] Moreover, a few previous studies had found that low muscle strength was related to a low level of serum albumin and hemoglobin. [10,11] Long-term exercise training program was proved to be an effective approach to improve both muscle and functional performance in older people with dynapenia.[12-15]

Flexi-bar is a type of vibration training. It consists of a bar and two weighty rubbers at each end of the bar. [16] Compared to conventional training, it is portable and feasible for physical training in the older population, particularly those with dynapenia. Some previous studies have found long-term flexi-bar having positive effects on muscle mass in young people [17] and physical function in older people.[18,19] It was reported that the thickness of transversus abdominis muscle of young university adults increased 2.4 mm after a 6-month (48 times) flexi-bar training program, which was statistically significantly different from the control group (0.9mm).[17] Lee et al. (2018) found that the score of Berg Balance Scale (BBS) increased 3.2, and the duration of completion of Timed-up-and-go test (TUG) and 10-meter walking test (10MWT) significantly decreased 4.2s and 4.6s, respectively, after 4 weeks of flexi-bar training (20 times) in older people with chronic stroke.[19] Although there was no direct evidence for muscle strength, Meliva et al. (2010) recorded the electromyography of biceps brachii, triceps brachii, rectus femoris, and

1
2
3 vastus lateralis during one set of flexi-bar training and concluded that flexi-bar training
4
5 could induce a stronger training stimulus on the muscle during submaximal exercise.[16]
6
7 These findings indicate that flexi-bar training might be an effective approach to enhance
8
9 muscle strength at the submaximal level.
10
11

12
13 Regarding to the findings of the previous studies, flexi-bar might be an effective
14
15 and safe training device for the older people with dynapenia. Considering the limited
16
17 studies conducted in the population with dynapenia, it is meaningful to examine the
18
19 effects of flexi-bar on muscle and physical performance in the older people with
20
21 dynapenia. Thus, the objective of this study is to investigate the effects of a 12-week
22
23 flexi-bar training program on muscle strength and physical function in the older people
24
25 with dynapenia.
26
27

28 **METHODS AND ANALYSIS**

29 **Participants**

30
31
32
33 The advertisement will be put on the notice board in the Health Service Centers in
34
35 General Hospital of the Yangtze River Shipping, Wuhan. Participants aged 65 years or
36
37 above attending the Health Center will be invited to a screening test of handgrip
38
39 strength measurement. Men and women with muscle strength less than 26kg and 18kg,
40
41 respectively, will be diagnosed as dynapenia.[20] Participants with severe heart
42
43 problem, neuro-degenerative diseases, vestibular disorders, cognitive impairment,
44
45 severe osteoporosis, visual impairment or mental diseases will be excluded from this
46
47 study. All participants will give their written consent to the principal investigator (NW)
48
49 before participating in the study. Only the principal investigator (NW) can access the
50
51 personal information of the study participants, which will be kept confidentially during
52
53 and after the study. The procedures were reviewed and approved by the Human Ethics
54
55
56
57
58
59
60

1
2
3
4 Review Board of Wuhan Brain Hospital (General Hospital of the Yangtze River
5
6 Shipping) before the commencement of the study (#L20200013). The clinical
7
8 registration number is ISRCTN 14316668 on 6th Nov 2020.
9
10
11 <https://doi.org/10.1186/ISRCTN14316668>
12
13

14 Randomization and blinding

15
16
17 This protocol was designed as a single-blinded randomized controlled trial,
18
19 adhering to Standard Protocol Items: Recommendations for Interventional Trials
20
21 guidelines. The participants will be randomized to flexi-bar, placebo and control groups
22
23 (no training). Each participants will be given an identification number by the main
24
25 investigator (NW), who will perform the randomization using a computer program
26
27 (Research Randomizer Form www.randomizer.org/). All training sessions will be
28
29 conducted under the supervision of a physical therapist, who will be blinded to the
30
31 randomization. The assessments and data analysis will be performed by a researcher
32
33 (XXW). Two research assistant (LC and MYLyu) will be responsible for data entry
34
35 (double data entry). Both of them will be blinded to randomization and intervention.
36
37
38
39
40
41
42

43 Patient and public involvement

44
45 Patients or members of the public will not be involved in this study. The research
46
47 design, enrolment, allocation, interventions and assessments will be conducted by the
48
49 trained researchers and physical therapists.
50
51

52 Interventions

53
54 A total of 36 training sessions (3 times/week, 12 weeks) will be conducted at
55
56 Health Service Centers. Each training session will include 10 sets of 30-second
57
58
59
60

1
2
3
4 vibration or sham exercises. One minute of rest period will be given between training
5
6 set to avoid over-exertion of the participants. During training, the flexi-bar group will
7
8 hold a flexi-Bar (FLEXI-BAR®; Flexi-Sports, Germany) with the shoulder flexed 90°
9
10 to perform an up-and-down vibration exercise. The participants will be instructed to
11
12 active the flexi-bar at individual highest frequency. The placebo group will hold the
13
14 same flexi-bar with no active vibration workout. During the training sessions, the
15
16 participants will be asked to stand with a knee angle of 120°. [21] To cater to mission
17
18 appointments, extra sessions will be arranged to make sure all participants will
19
20 completer the same number of training sessions. The training sessions will be
21
22 supervised by a physical therapist, who will be blinded to the randomization. Any
23
24 adverse event will be reported to the Human Ethics Review Board of Wuhan Brain
25
26 Hospital (General Hospital of the Yangtze River Shipping) and the intervention will be
27
28 discontinued for the particular participant. The control group will receive no additional
29
30 exercise training during the study. All participants will be asked to maintain their
31
32 normal lifestyle during the training and follow-up period.
33
34
35
36
37
38
39
40
41
42

43 Outcome variables

44
45 The primary outcomes, including handgrip muscle strength, five-repetition sit-to-
46
47 stand test (5STS), 10-meter walking test (10MWT) and timed-up-and-go test (TUG)
48
49 will be measured at baseline, post-intervention (1 day after training completion) and 12
50
51 weeks after training completion to investigate the effects of flexi-bar training on
52
53 physical performance in the older people with dynapenia. The levels of serum albumin
54
55 and hemoglobin will be examined as the secondary outcomes at baseline and post-
56
57
58
59
60

intervention (1 day after training completion) to explore the possible mechanisms of flexi-bar training on muscle strength. To promote the retention, all assessments will be free and transportation fee will be reimbursed. The study plan for recruitment, interventions, and assessment for the participants is summarized in Table 1.

TIMEPOINT	STUDY PERIOD					
	Enrolment	Allocation	Post-allocation			Close-out
	Day 0	week 0	Week 12	Week 24	After Week 24	
ENROLMENT:						
Eligibility screen	X					
Informed consent	X					
Randomization	X					
Allocation	X					
INTERVENTIONS:						
Flexi-bar group		←————→				
Sham group		←————→				
Control group		←————→				
ASSESSMENTS:						
Five-repetition sit-to-stand test		X	X	X		
10-meter walking test		X	X	X		
Timed-up-and-go test		X	X	X		
serum albumin		X	X	X		
hemoglobin		X	X			

Table 1 Timetable of activities planned during the study.

1
2
3
4 The maximum muscle strength of dominant side will be measured using hand-held
5
6 dynamometry (kg; CAMRY® Model EH101). Participants will be instructed to stand
7
8 straight with arms close to the body and the elbow flexed at 90°. Participants will be
9
10 then asked to squeeze the dynamometer as hard as possible. The maximum value of
11
12 three trials will be used for analyses.
13
14
15

16
17 The TUG was recommended as a suitable assessment for balance and physical
18
19 function in the older people with low muscle strength.[21] Participants performed this
20
21 test with their regular footwear. They will stand up from an armchair, walk a distance
22
23 of 3 meters, turn and walk back to the chair, and sit down with their normal pace without
24
25 help from another person. The average time of two trials will be used in the data analysis.
26
27
28
29

30 The 5STS is a reliable and valid assessment for physical function in the older
31
32 people. [21] The participant will sit on a chair with a height of 43-47cm with back
33
34 against the chair, arms crossed on the chest, feet comfortably placed on the floor. When
35
36 the tester will say “start”, the participant will rise from the chair to assume a full
37
38 standing position and return to a sitting position for five times without rest in between.
39
40 The time taken to complete the test will be recorded and the average time of two tests
41
42 will be calculated.
43
44
45
46
47

48 The 10MWT will be assessed at self-preferred and maximum walking speed. It is
49
50 used as a golden tool to evaluate the mobility in the older people. [21] The time will be
51
52 measured only for the middle 6 meters. Walking aid is allowed in this test. The average
53
54 walking speed of three trials will be in the data analysis.
55
56
57

58 The levels of serum albumin and hemoglobin will be measured in complete blood
59
60

1
2
3
4 count. Blood will be collected from the antecubital vein with participants seated after a
5
6 12-hour fasting period. After collection, tubes containing ethylenediamine tetra-
7
8 aceticacid plus samples will be centrifuged at 3.000 g for 15 min and plasma aliquots
9
10 stored at -70°C until analysis.
11
12

13 14 Sample size calculation

15
16
17 To date, no study has examined the long-term effects of flexi-bar training in the
18
19 older people with dynapenia. Thus, this study adopted an effect size of 0.27 to estimate
20
21 the sample size, as reported in a previous study investigating the effects of 12-week
22
23 power training program on TUG in the older people with dynapenia [13]. Since this
24
25 study involved two factors (two groups and three times of assessments), the sample size
26
27 was calculated to be 30 for each group with a power of 0.8 and α value of 0.05 using
28
29 the software (GPower 3.1). In consideration of 20% dropout rate, the total sample size
30
31 was 114.
32
33
34
35
36

37 Patient and public involvement

38
39 Patients or members of the public will not be involved in this study. The research
40
41 design, enrolment, allocation, interventions and assessments will be conducted by the
42
43 trained researchers.
44
45
46
47

48 Data analysis

49
50 To compare the baseline characteristics of the three groups, one-way analysis of
51
52 variance (ANOVA) (for data with normal distribution) or Kruskal-Wallis test (for data
53
54 with non-normal distribution) will be conducted. Two-way repeated-measures
55
56 ANOVA (time \times group) or Friedman test will be used to explore the effect of flexi-bar
57
58
59
60

1
2
3
4 training on muscle strength and physical performance in the people with dynapenia.
5
6 The last observation carried forward of an intention-to-treat analysis will be used for
7
8 data analysis. Descriptive analyses will be reported as means \pm standard deviations.
9
10 SPSS 20.0 (SPSS Inc., Chicago, Illinois, USA) will be used for statistical analysis. The
11
12 significance level will be set at $p < 0.05$, unless stated otherwise.
13
14
15

16 17 Ethics and dissemination

18
19 The procedures of this study were reviewed and approved by the Human Ethics
20
21 Review Board of Wuhan Brain Hospital (General Hospital of the Yangtze River
22
23 Shipping) on 29th Sep 2020 (L20200013). The findings of this study will be published
24
25 in peer-reviewed journals and presented at conferences. Meanwhile, the results will be
26
27 disseminated to the study participants.
28
29
30
31

32 33 DISCUSSION

34
35 To the best of our knowledge, this is the first study to investigate the effects of
36
37 flexi-bar training on muscle strength and physical performance in the older people with
38
39 dynapenia. Two previous studies had investigated the effects of flexi-bar training
40
41 physical performance in the older population.[18,19] They had reported that the
42
43 performance in TUG and 10MWT were improved after long-term flexi-bar training.[18]
44
45 However, there was no placebo group in their studies. Thus, it is premature to draw a
46
47 conclusion from these two studies.
48
49
50
51

52
53 Some previous studies had pointed that the older people with lower muscles
54
55 strength would have lower levels of albumin and hemoglobin.[22-24] One population-
56
57 based cross-sectional study reported serum albumin and hemoglobin to be positively
58
59
60

1
2
3
4 associated with muscle strength and balance; however, negatively with instrumental
5
6 activities of daily living in the community-dwelling population aged 55 years and
7
8 above.[22]
9

10
11 The strengths of this study are as follows: First, this is the first study to investigate
12
13 the effects of flexi-bar training on muscle strength and physical performance in the
14
15 older population with dynapenia. In this study, we will attempt to determine whether a
16
17 12-week flexi-bar training program would influence the level of albumin and
18
19 hemoglobin, which might explain the effect of flexi-bar training on the muscle strength
20
21 in the older people with dynapenia. Second, there will be a placebo group in this study,
22
23 which can rule out the effect of static squatting.
24
25
26
27
28
29

30 The limitations of this study are as follows: First, the muscle loading might not be
31
32 unified since the flexi-bar is an individually active induced training device. However,
33
34 the physical therapist will ask the participants to try their best to active the flexi-bar
35
36 during training. If participants do not try their best, the flexi-bar will stop vibrating. In
37
38 this case, the therapist will remind the participants to active the flexi-bar more
39
40 intensively. Considering the participants in our study might be at a different level of
41
42 health condition, it is better and safe to training them with individual efforts. Thus,
43
44 unified muscle loading might not be suitable for our participants. Second, due to
45
46 practical consideration, this study is designed as a single-blinded randomized controlled
47
48 trial, and not double-blinded.
49
50
51
52
53
54

55 **ACKNOWLEDGEMENT**

56
57
58 We would thank doctors, nurses and physical therapists of Department of
59
60

1
2
3
4 Rehabilitation of Wuhan Brain Hospital (General Hospital of the Yangtze River
5
6 Shipping) for their assistance.
7

8 **CONTRIBUTORS**

9
10 NW made substantial contributions to conception and design. XXW, MYL and
11
12 LC will collect and analyze data. The manuscript was drafted by NW.
13
14

15 **FUNDING STATEMENT**

16
17 This work was supported by Natural Science Foundation of Hubei Province
18
19 (Project #2019CFB349).
20
21

22 **ERHICS APPROVAL**

23
24 The Human Ethics Review Board of Wuhan Brain Hospital (General Hospital of
25
26 the Yangtze River Shipping) (#L20200013).
27
28

29 **CONFLICTS OF INTEREST**

30
31 The authors declared no potential conflicts of interest with respect to the research,
32
33 authorship, and/or publication of this article.
34
35

36 **REFERENCES**

- 37
38
39 1. Clark BC, Manini TM. Sarcopenia \neq dynapenia. J Gerontol A Biol Sci Med Sci.
40
41 2008;63(8):829-834.
42
43
44 2. Borges VS, Lima-Costa MFF, Andrade FB. A nationwide study on prevalence and
45
46 factors associated with dynapenia in older adults: ELSI-Brazil. Cad Saude Publica.
47
48 2020;36(4):e00107319.
49
50
51
52 3. Tessier AJ, Wing SS, Rahme E, et al. Physical function-derived cut-points for the
53
54 diagnosis of sarcopenia and dynapenia from the Canadian longitudinal study on aging.
55
56 J Cachexia Sarcopenia Muscle. 2019;10(5):985-999.
57
58
59 4. Clark BC, Manini TM. What is dynapenia? Nutrition. 2012;28(5):495-503.
60

- 1
2
3
4 5. Gadelha AB, Neri SGR, Vainshelboim B, et al. Dynapenic abdominal obesity and
5
6 the incidence of falls in older women: a prospective study. *Aging Clin Exp Res.*
7
8
9 2020;32(7):1263-1270.
10
- 11 6. Hasselgren L, Olsson LL, Nyberg L. Is leg muscle strength correlated with
12
13 functional balance and mobility among inpatients in geriatric rehabilitation? *Arch*
14
15
16
17 *Gerontol Geriatr.* 2011;52(3):e220-225.
18
- 19 7. Manini TM, Visser M, Won-Park S, et al. Knee extension strength cutpoints for
20
21 maintaining mobility. *J Am Geriatr Soc.* 2007;55(3):451-457.
22
23
- 24 8. Xue QL, Walston JD, Fried LP, et al. Prediction of risk of falling, physical
25
26 disability, and frailty by rate of decline in grip strength: the women's health and aging
27
28 study. *Arch Intern Med.* 2011;171(12):1119-1121.
29
30
- 31 9. Newman AB, Kupelian V, Visser M, et al. Strength, but not muscle mass, is
32
33 associated with mortality in the health, aging and body composition study cohort. *J*
34
35
36
37 *Gerontol A Biol Sci Med Sci.* 2006;61(1):72-77.
38
- 39 10. Penninx B, Pahor M, Cesari M, et al. Anemia is associated with disability and
40
41 decreased physical performance and muscle strength in the elderly. *J Am Geriatr*
42
43
44
45 *Soc.* 2004;52(5):719-724.
46
- 47 11. Schalk B, Deeg D, Penninx B, et al. Serum albumin and muscle strength: a
48
49 longitudinal study in older men and women. *J Am Geriatr Soc.* 2005;53(8):1331-
50
51
52
53 1338.
54
- 55 12. Barbat-Artigas S, Filion ME, Dupontgand S, et al. Effects of tai chi training in
56
57
58
59
60 dynapenic and nondynapenic postmenopausal women.

1
2
3
4 Menopause. 2011;18(9):974-979.
5

6
7 13. Carvalho LP, Pion CH, El Hajj Boutros G, et al. Effect of a 12-week mixed power
8
9 training on physical function in dynapenic-obese older men: does severity of
10
11 dynapenia matter? Aging Clin Exp Res. 2019;31(7):977-984.
12

13
14 14. Correa CS, Cunha G, Marques N, et al. Effects of strength training, detraining and
15
16 retraining in muscle strength, hypertrophy and functional tasks in older female adults.
17
18 Clin Physiol Funct Imaging. 2016;36(4):306-310.
19

20
21 15. Yamada M, Kimura Y, Ishiyama D, et al. Synergistic effect of bodyweight
22
23 resistance exercise and protein supplementation on skeletal muscle in sarcopenic or
24
25 dynapenic older adults. Geriatr Gerontol Int. 2019;19(5):429-437.
26
27

28
29 16. Mileva KN, Kadr M, Amin N, et al. Acute effects of flexi-bar vs. sham-bar
30
31 exercise on muscle electromyography activity and performance. J Strength Cond Res.
32
33 2010;24(3):737-748.
34
35

36
37 17. Lee SJ, Kim YN, Lee DK. The effect of flexi-bar exercise with vibration on trunk
38
39 muscle thickness and balance in university students in their twenties. J Phys Ther Sci.
40
41 2016;28(4):1298-1302.
42
43

44
45 18. Lee DK, Han JW. Effects of active vibration exercise using a flexi-bar on balance
46
47 and gait in patients with chronic stroke. J Phys Ther Sci. 2018;30(6):832-834.
48
49

50
51 19. Lee DK, Kim YN, Park CB, et al. The effect of actively induced vibration using
52
53 shoulder joint on pain and dysfunction in patients with low back pain. J Phys Ther
54
55 Sci. 2018;30(1):23-26.
56
57

58
59 20. Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian
60

- 1
2
3
4 Working Group for Sarcopenia. *J Am Med Dir Assoc*. 2014;15(2):95-101.
5
6
7 21. Wei N, Pang MY, Ng SS, et al. Optimal frequency/time combination of whole
8
9 body vibration training for developing physical performance of people
10
11 with sarcopenia: a randomized controlled trial. *Clin Rehabil*. 2017;31(10):1313-1321.
12
13
14 22. Aung KCY, Feng L, Yap KB, et al. Serum albumin and hemoglobin are
15
16 associated with physical function in community-living older persons in Singapore. *J*
17
18 *Nutr Health Aging*. 2011;15(10):877-882.
19
20
21
22 23. Lee HN, Chang YS, Wu YH, et al. Sarcopenia in female patients with Alzheimer's
23
24 disease are more likely to have lower levels of haemoglobin and 25-hydroxyvitamin
25
26
27 D. *Psychogeriatrics*. 2020;20(6):858-864.
28
29
30 24. Can B, Kara O, Kizilarslanoglu MC, et al. Serum markers of inflammation and
31
32 oxidative stress in sarcopenia. *Aging Clin Exp Res*. 2017;29(4):745-752.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	_____1_____
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	_____2_____
	2b	All items from the World Health Organization Trial Registration Data Set	<u>2 registration</u> <u>website</u> _____
Protocol version	3	Date and version identifier	_____2_____
Funding	4	Sources and types of financial, material, and other support	_____11_____
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	_____1_____
	5b	Name and contact information for the trial sponsor	_____1_____
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	_____11_____
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	_____13_____

1 **Introduction**

2

3 Background and 6a Description of research question and justification for undertaking the trial, including summary of relevant 3-4

4 rationale studies (published and unpublished) examining benefits and harms for each intervention

5

6 6b Explanation for choice of comparators 7

7

8 Objectives 7 Specific objectives or hypotheses 4

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),

11 allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 6

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will 5

17 be collected. Reference to where list of study sites can be obtained

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and 5-6

20 individuals who will perform the interventions (eg, surgeons, psychotherapists)

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be 5-6

23 administered

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose 7

26 change in response to harms, participant request, or improving/worsening disease)

27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence 8

29 (eg, drug tablet return, laboratory tests)

30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 7

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood 7-8

35 pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen

36 efficacy and harm outcomes is strongly recommended

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for 8

41 participants. A schematic diagram is highly recommended (see Figure)

42

43

44

45

46

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	_____ 10 _____
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	_____ 5 _____
5				

6 **Methods: Assignment of interventions (for controlled trials)**

7 Allocation:

8				
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	_____ 6 _____
11	generation			
12				
13				
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	_____ 6 _____
17	concealment			
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	_____ 6 _____
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	_____ 5 _____
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	_____ 5 _____
28				
29				
30				

31 **Methods: Data collection, management, and analysis**

32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	_____ 7-10 _____
34	methods			
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	_____ 8 _____
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	<u>6</u>
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	<u>10</u>
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	<u>/</u>
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	<u>10</u>
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>the study period is relatively short</u>
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>No interim analyses</u>
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	<u>7</u>
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>no auditing</u>
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	<u>6</u>
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	<u>/</u>
38				
39				
40				
41				
42				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	_____6_____
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	_____/_____
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	_____6_____
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____12_____
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	_____12_____
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	_____/_____
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	_____12_____
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	_____13_____
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____6_____
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	<u>The form is in Chinese, added as supplemental material</u>
32				
33				
34				
35				
36	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	_____/_____
37				
38				
39				

1 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
2 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
3 [“Attribution-NonCommercial-NoDerivs 3.0 Unported”](#) license.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

BMJ Open

The effects of flexi-bar training on muscle strength and physical performance in older people with dynapenia: the protocol of a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-048629.R2
Article Type:	Protocol
Date Submitted by the Author:	30-Jun-2021
Complete List of Authors:	WEI, Ning; Wuhan Polytechnic University, Wang, Xinxin; Wuhan Polytechnic University CHEN, Ling; Wuhan Polytechnic University Lyu, Mengyu; Wuhan Polytechnic University
Primary Subject Heading:	Geriatric medicine
Secondary Subject Heading:	Geriatric medicine
Keywords:	REHABILITATION MEDICINE, GERIATRIC MEDICINE, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 Protocol

5
6 The effects of flexi-bar training on muscle strength and physical performance in
7
8
9 older people with dynapenia: the protocol of a randomised controlled trial

10
11 Ning Wei*. Room 309, Department of Rehabilitation Sciences, College of Health
12
13 Science & Nursing, Wuhan Polytechnic University, Hubei, China. Email:
14
15 Nicole.weining@whpu.edu.cn; Tel: +86-83956736; Fax: +86-83956736.
16
17

18
19 Xinxin Wang. Department of Rehabilitation Sciences, College of Health Science
20
21 & Nursing, Wuhan Polytechnic University, Hubei, China.
22
23

24
25 Ling Chen. Department of Rehabilitation Sciences, College of Health Science &
26
27 Nursing, Wuhan Polytechnic University, Hubei, China.
28
29

30
31 Mengyu Lyu. Department of Rehabilitation Sciences, College of Health Science
32
33 & Nursing, Wuhan Polytechnic University, Hubei, China.
34

35 **Correspondence should be sent to Ning Wei.**
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Dynapenia is a new term that is used to describe the age-related loss of muscle strength. Flexi-bar training is a safe and feasible device for older people with dynapenia. This study will investigate the effects of a 12-week flexi-bar training programme on muscle strength and physical function in older people with dynapenia.

Methods and analysis: A total of 114 participants (aged more than 65 years) with age-related muscle loss will participate in a 12-week flexi-bar training programme. The participants will be randomly divided into three groups, namely flexi-bar, placebo, and control, with equal number of participants in each group. The assessments will be conducted at pre-, post-intervention, and 12 weeks after training completion. The primary outcome is Timed-up-and-go test. The secondary outcomes are five-repetition sit-to-stand, 10-metre walking test, handgrip strength, as well as the serum albumin and haemoglobin levels.

Ethics and dissemination: The procedures of this study were reviewed and approved by the Human Ethics Review Board of Wuhan Brain Hospital (General Hospital of the Yangtze River Shipping) on 29 Sep 2020 (L20200013). The findings of this study will be published in peer-reviewed journals and presented at conferences.

Word count: 2247

The trial was registered on 6 Nov 2020. The trial registration number is ISRCTN 14316668 (<https://doi.org/10.1186/ISRCTN14316668>).

Strengths and limitations of this study

- This study is the first parallel randomised controlled trial on the effects of

1
2
3
4 a 12-week flexi-bar training programme on muscle strength and physical function
5
6 in older people with dynapenia, and the study design involves a placebo group.
7
8

9 ● This study, comprising 12-week flexi-bar training and 12-week follow-up,
10
11 can accurately examine the effects of flexi-bar on older people with dynapenia.
12
13

14 ● The first limitation of this study is that the muscle loading of each
15
16 participant will not be uniform.
17
18

19 ● The second limitation is that the sample size may be insufficient for the
20
21 secondary outcome variables.
22
23

24 ● The third limitation is the single-blinded design.
25
26

27 Key words: rehabilitation medicine, geriatric medicine, musculoskeletal disorders
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Dynapenia is the age-related loss of muscle strength and was defined by Clark and Manini in 2008.[1] The prevalence of dynapenia is more than 20% in some countries.[2,3] The mechanisms of dynapenia remain unclear; however, age-related biological factors, unhealthy lifestyle, and mental-health variables have been identified as the possible factors contributing to dynapenia.[4,5] Age-related loss of muscle strength is strongly associated with a high risk of falls,[6] poor physical performance,[7,8] disability,[9] and mortality.[10] Moreover, a few studies have reported that low muscle strength is related to a low level of serum albumin and haemoglobin.[11,12] Long-term exercise training programme has been proved to be an effective approach to improve both muscle and functional performance in older people with dynapenia.[13-16]

Flexi-bar is a type of vibration device, and it consists of a bar, with two weighty rubbers at each end of the bar.[17] Some studies have reported that long-term flexi-bar training has positive effects on the muscle mass,[18,19] muscle strength,[20] and physical performance.[21,22] A study reported that the thickness of the transversus abdominis muscle of young university adults increases to 2.4 mm after a 6-month (48 times) flexi-bar training programme.[18] In another study, the overweight adults with a 12-week flexi-bar training programme exhibited a significant increase in handgrip strength, which was significantly different from that of the control group.[20] In a study on the physical performance by Lee et al. (2018), older people with chronic stroke exhibited significant improvement in the score of Berg Balance Scale (BBS), the duration of completion of Timed-up-and-go test (TUG), and 10-metre walking test (10MWT) after 4 weeks of flexi-bar training (20 times).[21] Moreover, the flexi-bar training could induce a strong stimulus on the muscle during submaximal

1
2
3 exercise,[17,23] which could be the indirect evidence for supporting the positive effect
4 of flexi-bar training on muscle strength. These findings suggest that flexi-bar training
5 might be an effective approach to enhance muscle strength and physical performance
6 at the submaximal level.
7
8
9
10

11
12 According to the findings of the previous studies, flexi-bar might be an effective
13 and safe training device for older people with dynapenia. Considering the inadequacy
14 of the number of studies conducted in the population with dynapenia, examining the
15 effects of flexi-bar training on the muscle and physical performance in older people
16 with dynapenia seems meaningful. The present study aims to investigate the effects of
17 a 12-week flexi-bar training programme on muscle strength and physical function in
18 older people with dynapenia.
19
20
21
22
23
24
25
26
27

28 **METHODS AND ANALYSIS**

29 **Participants**

30
31
32
33 The advertisement will be put on the notice board in the Health Service Centres in
34 General Hospital of the Yangtze River Shipping, Wuhan. Participants aged 65 years or
35 more attending the Health Centre will be invited to a screening test of handgrip strength
36 measurement. Men and women with muscle strength less than 26 kg and 18 kg,
37 respectively, and diagnosed as having dynapenia will be included.[24] Participants with
38 severe heart diseases, neuro-degenerative diseases, vestibular disorders, cognitive
39 impairment, severe osteoporosis, visual impairment, or mental diseases will be
40 excluded from this study. All participants will provide their written consent to the
41 principal investigator (NW) before participating in the study. Only the principal
42 investigator (NW) will be able to access the personal information of the study
43 participants, and the information will be kept confidential during and after the study.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 The procedures have been reviewed and approved by the Human Ethics Review Board
5
6 of Wuhan Brain Hospital (General Hospital of the Yangtze River Shipping;
7
8 #L20200013). The trial was registered on 6 Nov 2020, and the clinical registration
9
10 number is ISRCTN 14316668 (<https://doi.org/10.1186/ISRCTN14316668>).
11
12

13 14 Randomisation and blinding 15

16
17 This protocol was designed as a single-blinded randomised controlled trial in
18
19 accordance with the Standard Protocol Items: Recommendations for Interventional
20
21 Trials guidelines. The participants will be randomised into flexi-bar, placebo, and
22
23 control groups (no training). Each participant will be provided an identification number
24
25 by the main investigator (NW), who will perform the randomisation using a computer
26
27 programme (Research Randomizer Form; www.randomizer.org/). All training sessions
28
29 will be conducted under the supervision of a physical therapist, who will be blinded to
30
31 the randomisation. The assessments and data analysis will be performed by a researcher
32
33 (XXW). Two research assistants (LC and MYLyu) will be responsible for data entry
34
35 (double data entry), and both of them will be blinded to randomisation and intervention.
36
37
38
39
40
41
42

43 Interventions 44

45
46 A total of 36 training sessions (3 times/week, 12 weeks) will be conducted at
47
48 Health Service Centres. Each training session will include 10 sets of 30-second
49
50 vibration or sham exercises. One minute of rest period will be given between training
51
52 sets to avoid over-exertion of the participants. During training, the flexi-bar group will
53
54 hold a flexi-Bar (FLEXI-BAR®; Flexi-Sports, Germany), with the shoulder flexed at
55
56 90°, to perform an up-and-down vibration exercise. The participants will be instructed
57
58
59
60

	STUDY PERIOD			
	Enrolm	Allocation	Post-allocation	Close-out

to activate the flexi-bar at the highest individual frequency. The placebo group will hold the same flexi-bar with no active vibration workout. During the training sessions, the participants will be asked to stand with a knee angle of 120°. [25] To cater for missing appointments, extra sessions will be arranged to ensure that all the participants complete the equal number of training sessions. The training sessions will be supervised by a physical therapist, who will be blinded to the randomisation. Any adverse event will be reported to the Human Ethics Review Board of Wuhan Brain Hospital (General Hospital of the Yangtze River Shipping), and the intervention will be discontinued for the participant reporting adverse events. The control group will receive no additional exercise training during the study period. All the participants will be asked to maintain their normal lifestyle during the training and follow-up period.

Outcome variables

The primary outcome is TUG, whereas the secondary outcomes are handgrip muscle strength, five-repetition sit-to-stand test (5STS), 10-metre walking test (10MWT), as well as the serum albumin and haemoglobin levels. Both primary and secondary outcomes will be measured at baseline, post-intervention (1 day after training completion), and 12 weeks after training completion. To promote the retention, all the assessments will be provided free of cost, and transportation fee will be reimbursed. The study plan for recruitment, interventions, and assessment for participants is summarized in Table 1.

	ent				
TIMEPOINT	Day 0	week 0	Week 12	Week 24	After Week 24
ENROLMENT:					
Eligibility screen	X				
Informed consent	X				
Randomisation	X				
Allocation	X				
INTERVENTIONS					
Flexi-bar group		←————→			
Sham group		←————→			
Control group		←————→			
ASSESSMENTS:					
Timed-up-and-go test		X	X	X	
10-metre walking test		X	X	X	
Five-repetition sit-to-stand test		X	X	X	
Handgrip strength		X	X	X	
Serum albumin		X	X	X	
Haemoglobin		X	X	X	

Table 1 Timetable of activities planned during the study

The TUG was recommended as a suitable assessment for balance and physical function in older people with low muscle function.[25] The participants will perform this test with their regular footwear. They will stand up from an armchair, walk a distance of 3 metres, turn and walk back to the chair, and sit down with their normal pace without taking help from another person. The average time of the two trials will

1
2
3
4 be used for data analysis.
5

6 The 5STS is a reliable and valid assessment for physical function in older
7 people.[25] The participant will sit on a chair of 43–47-cm height, with back against
8 the chair, arms crossed on the chest, and feet comfortably placed on the floor. When
9 the tester will say ‘start’, the participant will rise from the chair to assume a full standing
10 position and return to a sitting position, and this action will be repeated five times
11 without rest in between. The time taken to complete the test will be recorded, and the
12 average time of the two tests will be calculated.
13
14
15
16
17
18
19
20
21
22
23

24 The 10MWT will be assessed at a self-preferred and maximum walking speed. It
25 is used as a golden tool to evaluate the mobility in the older people.[25] The time will
26 be measured only for the middle 6 metres. Walking aid is allowed in this test. The
27 average walking speed of three trials will be for the data analysis.
28
29
30
31
32
33

34 The handgrip strength of the dominant side will be measured using a hand-held
35 dynamometer (kg; CAMRY® Model EH101). Participants will be instructed to stand
36 straight, with arms close to the body and the elbow flexed at 90°. The participants will
37 then be asked to squeeze the dynamometer as hard as possible. The maximum value of
38 the three trials will be used for analyses.
39
40
41
42
43
44
45
46
47

48 The serum albumin and haemoglobin levels will be measured. Blood will be
49 collected from the antecubital vein, with participants seated after a 12-h fasting period.
50 After collection, the tubes containing ethylenediamine tetra-acetic acid and samples will
51 be centrifuged at 3.000 g for 15 min, and plasma aliquots will be stored at –70°C until
52 analysis.
53
54
55
56
57
58
59
60

Sample size calculation

To date, no study has examined the long-term effects of flexi-bar training in older people with dynapenia. Thus, this study adopted an effect size of 0.27 to estimate the sample size, as reported in a previous study investigating the effects of 12-week power training programme on TUG in older people with dynapenia.[14] Since this study involved two factors (two groups and three times of assessments), the sample size calculated using a software (GPower 3.1) was 30 for each group, with a power of 0.8 and an α value of 0.05. Considering a 20% dropout rate, the total sample size will be 114.

Patient and public involvement

Patients or members of the public will not be involved in this study. The research design, enrolment, allocation, interventions, and assessments will be conducted by trained researchers.

Data analysis

To compare the baseline characteristics of the three groups, one-way analysis of variance (ANOVA) (for data with normal distribution) or Kruskal–Wallis test (for data with non-normal distribution) will be conducted. Two-way repeated-measures ANOVA (time \times group) or Friedman test will be used to explore the effect of flexi-bar training. The last observation, carried forward of an intention-to-treat analysis, will be used for data analysis. Descriptive analyses will be reported as means \pm standard deviations. SPSS 20.0 (SPSS Inc., Chicago, Illinois, USA) will be used for statistical analyses. The significance level will be set at $p < 0.05$, unless stated otherwise.

Ethics and dissemination

The procedures of this study were reviewed and approved by the Human Ethics Review Board of Wuhan Brain Hospital (General Hospital of the Yangtze River Shipping) on 29 Sep 2020 (L20200013). The findings of this study will be published in peer-reviewed journals and presented at conferences. Meanwhile, the results will be disseminated to the study participants.

DISCUSSION

To the best of our knowledge, this study is the first to investigate the effects of flexi-bar training on muscle strength and physical performance in older people with dynapenia. Two studies have investigated the effects of flexi-bar training on the physical performance in the older population.[21,22] The authors reported that the performance in TUG and 10MWT was improved after long-term flexi-bar training.[21] However, these studies had no placebo group. Thus, drawing a conclusion from these two studies is inappropriate.

Some studies have indicated that older people with low muscles strength exhibit low levels of albumin and haemoglobin.[26-28] One population-based cross-sectional study reported that serum albumin and haemoglobin levels are associated positively with muscle strength and balance but negatively with instrumental activities of daily living in the community-dwelling population aged 55 years and more.[26]

This study has some strengths. First, this study is the first to investigate the effects of flexi-bar training on muscle strength and physical performance in older population with dynapenia. In this study, we will attempt to determine whether a 12-week flexi-

1
2
3
4 bar training programme would influence the level of albumin and haemoglobin, which
5
6 might explain the effect of flexi-bar training on the muscle strength in older people with
7
8 dynapenia. Second, this study will involve a placebo group, which can rule out the
9
10 effect of static squatting.
11
12

13
14 The study will have some limitations. First, the muscle loading might not be
15
16 unified since the flexi-bar is an individually active induced training device. However,
17
18 the physical therapist will ask the participants to try their best to activate the flexi-bar
19
20 during training. If participants do not try their best, the flexi-bar will stop vibrating. In
21
22 this case, the therapist will remind the participants to activate the flexi-bar more
23
24 intensively. Considering that the participants in our study might be at a different level
25
26 of health condition, training them with individual efforts is an effective and safe
27
28 approach. Thus, uniform muscle loading might not be suitable for our participants.
29
30 Second, the sample size might be insufficient for assessing the secondary outcomes. In
31
32 this protocol, the sample size will be calculated according to the effect size of the
33
34 primary outcome. However, whether the sample size is adequate for each secondary
35
36 outcome remains uncertain. Third, due to practical consideration, this study is designed
37
38 as a single-blinded randomised controlled trial and not as a double-blinded trial.
39
40
41
42
43
44
45
46
47

48 **ACKNOWLEDGEMENT**

49
50 We thank doctors, nurses, and physical therapists of the Department of
51
52 Rehabilitation of Wuhan Brain Hospital (General Hospital of the Yangtze River
53
54 Shipping) for their assistance.
55
56

57 **CONTRIBUTORS**

58
59 NW made substantial contributions to conception and design. XXW, MYL, and
60

1
2
3 LC will collect and analyse data. The manuscript was drafted by NW.
4

5 **FUNDING STATEMENT**

6
7 This work was supported by the Natural Science Foundation of Hubei Province
8
9 (Project #2019CFB349).
10

11 **ERHICS APPROVAL**

12
13 The Human Ethics Review Board of Wuhan Brain Hospital (General Hospital of
14
15 the Yangtze River Shipping) (#L20200013).
16
17

18 **CONFLICTS OF INTEREST**

19
20 The authors declared no potential conflicts of interest with respect to the research,
21
22 authorship, and/or publication of this article.
23
24

25 **REFERENCES**

- 26
27
28
29 1. Clark BC, Manini TM. Sarcopenia \neq dynapenia. J Gerontol A Biol Sci Med Sci.
30
31 2008;63(8):829-834.
32
33
34 2. Borges VS, Lima-Costa MFF, Andrade FB. A nationwide study on prevalence and
35
36 factors associated with dynapenia in older adults: ELSI-Brazil. Cad Saude Publica.
37
38 2020;36(4):e00107319.
39
40
41
42 3. Tessier AJ, Wing SS, Rahme E, et al. Physical function-derived cut-points for the
43
44 diagnosis of sarcopenia and dynapenia from the Canadian longitudinal study on aging.
45
46 J Cachexia Sarcopenia Muscle. 2019;10(5):985-999.
47
48
49 4. Clark BC, Manini TM. What is dynapenia? Nutrition. 2012;28(5):495-503.
50
51
52
53 5. da Cunha Leme DE. Dynapenia in middle-aged and older persons with and without
54
55 abdominal obesity and the complex relationship with behavioral, physical-health and
56
57 mental-health variables: Learning Bayesian network structures. Clin Nutr ESPEN.
58
59
60

1
2
3
4 2021;42:366-372.
5

6 6. Gadelha AB, Neri SGR, Vainshelboim B, et al. Dynapenic abdominal obesity and
7 the incidence of falls in older women: a prospective study. *Aging Clin Exp Res.*
8
9 2020;32(7):1263-1270.
10
11

12
13
14 7. Hasselgren L, Olsson LL, Nyberg L. Is leg muscle strength correlated with
15 functional balance and mobility among inpatients in geriatric rehabilitation? *Arch*
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

22 8. Manini TM, Visser M, Won-Park S, et al. Knee extension strength cutpoints for
23 maintaining mobility. *J Am Geriatr Soc.* 2007;55(3):451-457.

27 9. Xue QL, Walston JD, Fried LP, et al. Prediction of risk of falling, physical
28 disability, and frailty by rate of decline in grip strength: the women's health and aging
29 study. *Arch Intern Med.* 2011;171(12):1119-1121.

35 10. Newman AB, Kupelian V, Visser M, et al. Strength, but not muscle mass, is
36 associated with mortality in the health, aging and body composition study cohort. *J*
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

43 11. Penninx B, Pahor M, Cesari M, et al. Anemia is associated with disability and
44 decreased physical performance and muscle strength in the elderly. *J Am Geriatr*
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

51 12. Schalk B, Deeg D, Penninx B, et al. Serum albumin and muscle strength: a
52 longitudinal study in older men and women. *J Am Geriatr Soc.* 2005;53(8):1331-
53
54
55
56
57
58
59
60

- 1
2
3
4 13. Barbat-Artigas S, Filion ME, Dupontgand S, et al. Effects of tai chi training in
5
6
7
8
9
10
11
12 14. Carvalho LP, Pion CH, El Hajj Boutros G, et al. Effect of a 12-week mixed power
13
14
15
16
17
18
19
20 15. Correa CS, Cunha G, Marques N, et al. Effects of strength training, detraining and
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
13. Barbat-Artigas S, Filion ME, Dupontgand S, et al. Effects of tai chi training in
dynamenic and nondynamenic postmenopausal women.
Menopause. 2011;18(9):974-979.
14. Carvalho LP, Pion CH, El Hajj Boutros G, et al. Effect of a 12-week mixed power
training on physical function in dynamenic-obese older men: does severity of
dynamenia matter? Aging Clin Exp Res. 2019;31(7):977-984.
15. Correa CS, Cunha G, Marques N, et al. Effects of strength training, detraining and
retraining in muscle strength, hypertrophy and functional tasks in older female adults.
Clin Physiol Funct Imaging. 2016;36(4):306-310.
16. Yamada M, Kimura Y, Ishiyama D, et al. Synergistic effect of bodyweight
resistance exercise and protein supplementation on skeletal muscle in sarcopenic or
dynamenic older adults. Geriatr Gerontol Int. 2019;19(5):429-437.
17. Mileva KN, Kadr M, Amin N, et al. Acute effects of flexi-bar vs. sham-bar
exercise on muscle electromyography activity and performance. J Strength Cond Res.
2010;24(3):737-748.
18. Lee SJ, Kim YN, Lee DK. The effect of flexi-bar exercise with vibration on trunk
muscle thickness and balance in university students in their twenties. J Phys Ther Sci.
2016;28(4):1298-1302.
19. Chung SH, You YY, Lee HJ, et al. Effects of stabilization exercise using flexi-bar
on functional disability and transverse abdominis thickness in patients with chronic
low back pain. J Phys Ther Sci. 2018;30(3):400-404.

- 1
2
3
4 20. Phanpheng Y, Hiruntrakul A. Phanpheng Y, et al. Effects of flexi bar training
5
6 model to health-related physical fitness in overweight adults. *J Phys Ther Sci.*
7
8
9 2020;32(8):489-495.
10
11 21. Lee DK, Han JW. Effects of active vibration exercise using a flexi-bar on balance
12
13 and gait in patients with chronic stroke. *J Phys Ther Sci.* 2018;30(6):832-834.
14
15 22. Lee DK, Kim YN, Park CB, et al. The effect of actively induced vibration using
16
17 shoulder joint on pain and dysfunction in patients with low back pain. *J Phys Ther*
18
19 *Sci.* 2018;30(1):23-26.
20
21 23. Kim JH, So KH, Bae YR, et al. A Comparison of Flexi-bar and General Lumbar
22
23 Stabilizing Exercise Effects on Muscle Activity and Fatigue. *J Phys Ther Sci.*
24
25 2014;26(2):229-33.
26
27 24. Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian
28
29 Working Group for Sarcopenia. *J Am Med Dir Assoc.* 2014;15(2):95-101.
30
31 25. Wei N, Pang MY, Ng SS, et al. Optimal frequency/time combination of whole
32
33 body vibration training for developing physical performance of people
34
35 with sarcopenia: a randomized controlled trial. *Clin Rehabil.* 2017;31(10):1313-1321.
36
37 26. Aung KCY, Feng L, Yap KB, et al. Serum albumin and hemoglobin are
38
39 associated with physical function in community-living older persons in Singapore. *J*
40
41 *Nutr Health Aging.* 2011;15(10):877-882.
42
43 27. Lee HN, Chang YS, Wu YH, et al. Sarcopenia in female patients with Alzheimer's
44
45 disease are more likely to have lower levels of haemoglobin and 25-hydroxyvitamin
46
47 D. *Psychogeriatrics.* 2020;20(6):858-864.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 28. Can B, Kara O, Kizilarlanoglu MC, et al. Serum markers of inflammation and
5
6 oxidative stress in sarcopenia. *Aging Clin Exp Res.* 2017;29(4):745-752.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	_____ 1 _____
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	_____ 2 _____
	2b	All items from the World Health Organization Trial Registration Data Set	<u>2 registration</u> <u>website</u> _____
Protocol version	3	Date and version identifier	_____ 2 _____
Funding	4	Sources and types of financial, material, and other support	_____ 13 _____
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	_____ 1 _____
	5b	Name and contact information for the trial sponsor	_____ 1 _____
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	_____ 13 _____
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	_____ 13 _____

1 **Introduction**

2

3 Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention 4-5

4

5

6 6b Explanation for choice of comparators 7

7

8 Objectives 7 Specific objectives or hypotheses 5

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 6

11

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained 5

17

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) 5-6

20

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered 5-6

23

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) 7

26

27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) 7

29

30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 7

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended 7-9

35

36

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) 8

41

42

43

44

45

46

1 Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including _____ 10 _____
 2 clinical and statistical assumptions supporting any sample size calculations

3
 4 Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size _____ 5 _____
 5

6 **Methods: Assignment of interventions (for controlled trials)**

7 Allocation:

8
 9
 10 Sequence 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any _____ 6 _____
 11 generation factors for stratification. To reduce predictability of a random sequence, details of any planned restriction
 12 (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants
 13 or assign interventions
 14
 15

16 Allocation 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, _____ 6 _____
 17 concealment opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned
 18 mechanism
 19

20 Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to _____ 6 _____
 21 interventions
 22
 23

24 Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome _____ 6 _____
 25 assessors, data analysts), and how
 26

27 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's _____ 6 _____
 28 allocated intervention during the trial
 29
 30

31 **Methods: Data collection, management, and analysis**

32
 33 Data collection 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related _____ 7-11 _____
 34 methods processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of
 35 study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.
 36 Reference to where data collection forms can be found, if not in the protocol
 37

38
 39 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be _____ 7&10 _____
 40 collected for participants who discontinue or deviate from intervention protocols
 41
 42

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	_____6_____
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	_____10_____
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	_____/_____
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	_____10_____
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>the study period is relatively short</u> _____
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>No interim analyses</u> _____
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	_____7_____
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>no auditing</u> _____
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	_____6_____
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	_____/_____
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	_____ 5 _____
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	_____ / _____
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	_____ 5 _____
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____ 13 _____
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	_____ 6 _____
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	_____ / _____
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	_____ 11 _____
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	_____ 13 _____
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____ 11 _____
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	<u>The form is in Chinese, added as supplemental material</u>
32				
33				
34				
35				
36	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	_____ / _____
37				
38				
39				

1 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
2 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
3 [“Attribution-NonCommercial-NoDerivs 3.0 Unported”](#) license.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only